Speaker Profile
Ph.D., CEO, MyOme
Biography
Premal Shah, Ph.D., is the CEO of MyOme, a genomics innovation company focused on preventive health through whole genome sequencing and polygenic risk scoring. With over 20 years of experience in biotech and healthcare, he is dedicated to advancing personalized medicine and genomics-driven health solutions. Previously, Premal was Co-Founder President at Ciitizen, a digital health company empowering patients with their own health data, where he oversaw operations and strategic development, including go-to-market strategies. Ciitizen was acquired by Invitae. Before Ciitizen, he served as CEO of Applied Proteomics, a company pioneering a blood-based colorectal cancer diagnostic test. Prior to that, he led corporate development at Genomic Health (now part of Exact Sciences). Premal began his career as a management consultant at Booz Company, focusing on front-office strategies. He holds a Ph.D. in computational biology from the California Institute of Technology, with several publications in the field.
Talk
Advancing Breast Cancer Risk Assessments with Natera
MyOmes Breast Cancer Polygenic Risk Score (PRS) introduces a next-gen approach to breast cancer risk by integrating PRS with clinical factors, and has been validated across diverse populations. iPRS is currently used with Nateras Empower test and Alabamas Catalyst program, with these case studies to be presented.
Clinical Dx Showcase:
MyOme
At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
